Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Director | March 11, 2026 | March 13, 2026 |
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Director · President and CEO | October 06, 2026 | October 08, 2026 |
| Xencor IncXNCR · Entity 4487 | Director | June 23, 2022 | June 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENANTA PHARMACEUTICALS INC
Report date March 11, 2026 · Filed March 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2036-03-11 | Direct | 20,000 |
Reported balance
After 2026-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-11 · Grant · Acquired 20,000 · Balance 20,000 F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.
IDEAYA Biosciences, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 690,695 |
Ending reported balance
After 2026-10-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 26,338 · Balance 717,033 Row 2 · 2026-10-06 · Sale · Disposed 25,538 · Balance 691,495 F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on July 7, 2026, in which the majority of the shares acquired upon the exercise of stock options were granted to the Reporting Person prior to the Issuer's initial public offering and are approaching their expiration date. F2: This transaction was executed in multiple trades in prices ranging from $37.00 to $37.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-10-06 · Sale · Disposed 800 · Balance 690,695 F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on July 7, 2026, in which the majority of the shares acquired upon the exercise of stock options were granted to the Reporting Person prior to the Issuer's initial public offering and are approaching their expiration date. F3: This transaction was executed in multiple trades in prices ranging from $38.23 to $38.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2028-02-26 | Direct | 23,116 |
Reported balance
After 2026-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-06 · Exercise / conversion · Disposed 26,338 · Balance 23,116 F4: The shares subject to the option are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on July 7, 2026, in which the majority of the shares acquired upon the exercise of stock options were granted to the Reporting Person prior to the Issuer's initial public offering and are approaching their expiration date.
F2: This transaction was executed in multiple trades in prices ranging from $37.00 to $37.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: This transaction was executed in multiple trades in prices ranging from $38.23 to $38.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4: The shares subject to the option are fully vested and exercisable.
Xencor Inc
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.58 · Expires 2032-06-23 | Direct | 21,412 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 21,412 · Balance 21,412 F1: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 2, 2022 19:44 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 260,000 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001567619-22-006124 · doc1.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 20:44 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 13,144 | $0.00 Strike: $48.58 | $0.00 |
DisclosureSEC source: 0001177648-21-000023 · edgar.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,144 Underlying: Common Stock · 13,144 shares Expires 2031-08-19 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over three years, beginning from the date of grant (August 19, 2021). Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 20:01 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 9,728 | $0.00 Strike: $36.01 | $0.00 |
DisclosureSEC source: 0001415889-21-003234 · form4-06252021_080633.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,728 Underlying: Common Stock · 9,728 shares Expires 2031-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 24, 2021, such that the total number of shares will be fully vested on June 24, 2022. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 19:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 195,000 | $0.00 Strike: $19.52 | $0.00 |
DisclosureSEC source: 0001567619-21-005112 · doc1.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2031-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 16:06 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-20-021549 · doc1.xml · derivative · entry 2 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,055 Underlying: Common Stock · 8,000 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 16:06 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 8,000 | $4.31 | $34,480.00 |
DisclosureSEC source: 0001567619-20-021549 · doc1.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 666,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2020 Filed Jun 29, 2020 20:36 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 13,953 | $0.00 Strike: $33.42 | $0.00 |
DisclosureSEC source: 0001209191-20-039304 · doc4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,953 Underlying: Common Stock · 13,953 shares Expires 2030-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 25, 2020, such that the total number of shares will be fully vested on June 25, 2021. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 17:33 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 47,564 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-20-008053 · doc1.xml · derivative · entry 2 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,055 Underlying: Common Stock · 47,564 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 17:33 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 47,564 | $4.31 | $205,000.84 |
DisclosureSEC source: 0001567619-20-008053 · doc1.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 16:04 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 215,000 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-20-004805 · doc1.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 215,000 shares Expires 2030-02-20 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 30, 2019 Filed Aug 1, 2019 12:20 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-19-015591 · doc1.xml · derivative · entry 2 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,619 Underlying: Common Stock · 15,000 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 30, 2019 Filed Aug 1, 2019 12:20 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 15,000 | $4.31 | $64,650.00 |
DisclosureSEC source: 0001567619-19-015591 · doc1.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 610,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 19:49 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 12,731 | $0.00 Strike: $39.08 | $0.00 |
DisclosureSEC source: 0001209191-19-039385 · doc4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,731 Underlying: Common Stock · 12,731 shares Expires 2029-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 26, 2019, such that the total number of shares will be fully vested on June 26, 2020. Read SEC document |
| June 26, 2018 Filed Jun 27, 2018 18:03 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $38.93 | $0.00 |
DisclosureSEC source: 0001209191-18-039699 · doc4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 26, 2018, such that the total number of shares will be fully vested on June 26, 2019. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 16:30 UTC | Xencor Inc XNCR · Entity 4487 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $22.20 | $0.00 |
DisclosureSEC source: 0001209191-17-041838 · doc4.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 22, 2017, such that the total number of shares will be fully vested on June 22, 2018. Read SEC document |
| June 23, 2016 Filed Mar 3, 2021 20:00 UTC Amendment | Xencor Inc XNCR · Entity 4487 | GrantStock Options · Derivative | 7,500 | $0.00 Strike: $14.43 | $0.00 |
DisclosureSEC source: 0001415889-21-001293 · form4a-03032021_080302.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2026-06-22 F1 · derivative.exercise_price: The initial filing incorrectly listed the exercise price at $14.83 per share due to an administrative error. F2 · derivative.exercise_date: 100% of the shares subject to the option vest on June 23, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.